Want to see IN:IPCALAB full AI Analyst Report?
IPCALAB Stock Chart & Stats
₹1762.70
₹14.90(0.85%)
At close: 4:00 PM EDT
₹1762.70
₹14.90(0.85%)
Day’s Range― - ―
52-Week Range₹1,252.95 - ₹1,941.40
Previous CloseN/A
Volume119.64K
Average Volume (3M)6.78K
Market Cap
₹455.72B
Enterprise Value₹417.40K
Total Cash (Recent Filing)₹11.98B
Total Debt (Recent Filing)₹8.09B
Price to Earnings (P/E)38.6
Beta0.20
Next Earnings
Nov 06, 2026Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)44.98
Shares Outstanding253,659,230
10 Day Avg. Volume6,645
30 Day Avg. Volume6,776
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)5.04
Price to Sales (P/S)4.21
P/FCF Ratio83.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.51
Revenue Forecast (FY)₹107.98B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet With Very Low LeverageA very low debt-to-equity (~0.10 in 2026) gives IPCA durable financial flexibility: it can fund capex, withstand regulatory or demand shocks, and pursue selective M&A or R&D without material refinancing risk, supporting long-term resilience and strategy execution.
Vertical Integration Across APIs And Finished DosagesOwning API manufacturing alongside finished-dose operations lowers input cost exposure, improves gross-margin capture on captive volumes, and strengthens supply-chain control. This structural integration supports margin durability, product reliability and competitiveness in export and partner markets over time.
Established Scale With Solid Gross And Net MarginsMaterial scale together with sustained gross (~44%) and net (~11.8%) margins indicate profitable operations and cost base leverage. Scale supports manufacturing efficiency, bargaining power with suppliers, and the ability to invest in quality/compliance—important durable advantages for pharma firms.
Bears Say
Meaningful Margin Compression Versus Earlier YearsPersistent margin compression signals structural cost pressures or adverse product-mix shifts; if not reversed it reduces return on capital and limits reinvestment capacity. For a manufacturing-led pharma business, sustained margin erosion can impair competitiveness and shareholder returns.
Slowing Revenue Growth Momentum (2026 Moderation)Top-line growth moderating to ~3.1% weakens operating leverage and makes it harder to offset margin pressures via scale. Over a multi-quarter horizon, slower organic growth increases reliance on new product approvals, market expansion, or partnerships to sustain long-term earnings growth.
Moderate Free-cash-flow Conversion Versus Net IncomeFCF conversion of ~0.43x of net income means earnings are absorbed by working capital and capex needs. That constrains internal funding for dividends, R&D or acquisitions and reduces financial flexibility despite low leverage, making sustained reinvestment or shareholder returns more challenging.
IPCA Laboratories Limited News
IPCALAB FAQ
What was IPCA Laboratories Limited’s price range in the past 12 months?
IPCA Laboratories Limited lowest stock price was ₹1252.95 and its highest was ₹1941.40 in the past 12 months.
What is IPCA Laboratories Limited’s market cap?
IPCA Laboratories Limited’s market cap is ₹455.72B.
When is IPCA Laboratories Limited’s upcoming earnings report date?
IPCA Laboratories Limited’s upcoming earnings report date is Nov 06, 2026 which is in 83 days.
How were IPCA Laboratories Limited’s earnings last quarter?
IPCA Laboratories Limited released its earnings results on Aug 13, 2026. The company reported ₹15.84 earnings per share for the quarter, beating the consensus estimate of ₹12.162 by ₹3.678.
Is IPCA Laboratories Limited overvalued?
According to Wall Street analysts IPCA Laboratories Limited’s price is currently Overvalued.
Does IPCA Laboratories Limited pay dividends?
IPCA Laboratories Limited pays a Annually dividend of ₹6 which represents an annual dividend yield of 0.35%. See more information on IPCA Laboratories Limited dividends here
What is IPCA Laboratories Limited’s EPS estimate?
IPCA Laboratories Limited’s EPS estimate is 14.
How many shares outstanding does IPCA Laboratories Limited have?
IPCA Laboratories Limited has 253,659,230 shares outstanding.
What happened to IPCA Laboratories Limited’s price movement after its last earnings report?
IPCA Laboratories Limited reported an EPS of ₹15.84 in its last earnings report, beating expectations of ₹12.162. Following the earnings report the stock price went up 1.692%.
Which hedge fund is a major shareholder of IPCA Laboratories Limited?
Currently, no hedge funds are holding shares in IN:IPCALAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IPCA Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
―
Neuland Laboratories Ltd.
―
Wockhardt Limited
―